Walleye Capital LLC Buys New Stake in The Oncology Institute, Inc. $TOI

Walleye Capital LLC bought a new position in The Oncology Institute, Inc. (NASDAQ:TOI) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 445,832 shares of the company’s stock, valued at approximately $2,421,000. Walleye Capital LLC owned 0.45% of Oncology Institute at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. LPL Financial LLC boosted its holdings in Oncology Institute by 1.5% during the fourth quarter. LPL Financial LLC now owns 270,885 shares of the company’s stock valued at $964,000 after acquiring an additional 3,900 shares during the period. AQR Capital Management LLC increased its stake in shares of Oncology Institute by 9.1% in the fourth quarter. AQR Capital Management LLC now owns 48,072 shares of the company’s stock worth $171,000 after purchasing an additional 4,007 shares during the period. HighTower Advisors LLC lifted its position in shares of Oncology Institute by 5.5% during the 4th quarter. HighTower Advisors LLC now owns 85,851 shares of the company’s stock worth $306,000 after purchasing an additional 4,489 shares during the last quarter. Cetera Investment Advisers lifted its position in shares of Oncology Institute by 35.0% during the 2nd quarter. Cetera Investment Advisers now owns 17,545 shares of the company’s stock worth $36,000 after purchasing an additional 4,545 shares during the last quarter. Finally, R Squared Ltd boosted its stake in Oncology Institute by 42.7% during the 1st quarter. R Squared Ltd now owns 16,353 shares of the company’s stock valued at $50,000 after purchasing an additional 4,891 shares during the period. Institutional investors and hedge funds own 36.86% of the company’s stock.

Insider Activity at Oncology Institute

In other Oncology Institute news, insider Yale Podnos sold 23,451 shares of the firm’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $5.38, for a total value of $126,166.38. Following the completion of the sale, the insider owned 259,527 shares in the company, valued at approximately $1,396,255.26. This trade represents a 8.29% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Jorey Chernett acquired 33,500 shares of Oncology Institute stock in a transaction on Wednesday, May 20th. The stock was purchased at an average price of $4.07 per share, with a total value of $136,345.00. Following the transaction, the insider directly owned 10,567,858 shares in the company, valued at approximately $43,011,182.06. This trade represents a 0.32% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders acquired 131,500 shares of company stock valued at $609,265. Insiders own 4.40% of the company’s stock.

Oncology Institute Stock Performance

NASDAQ:TOI opened at $5.19 on Friday. The firm’s 50-day moving average is $5.29 and its 200-day moving average is $4.03. The company has a market cap of $512.58 million, a price-to-earnings ratio of -14.02 and a beta of 0.39. The Oncology Institute, Inc. has a 52-week low of $2.32 and a 52-week high of $6.67.

Oncology Institute (NASDAQ:TOI) last released its earnings results on Thursday, August 6th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The company had revenue of $161.28 million for the quarter, compared to analyst estimates of $155.28 million. Equities analysts predict that The Oncology Institute, Inc. will post -0.18 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oncology Institute in a report on Friday, July 17th. Lake Street Capital initiated coverage on Oncology Institute in a research report on Monday, July 6th. They issued a “buy” rating and a $10.00 price target on the stock. BTIG Research upped their price target on Oncology Institute from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Thursday, July 9th. Finally, Needham & Company LLC increased their price objective on Oncology Institute from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Wednesday, June 17th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Oncology Institute currently has an average rating of “Moderate Buy” and a consensus target price of $8.50.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.